Tag: Bayer

April 13, 2022 Off

Bayer receives approval for precision oncology treatment Vitrakvi in China

By Author

The Center of Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) approved Bayer’s larotrectinib, under the brand name Vitrakvi, for the treatment of adult and pediatric patients with advanced solid tumors that harbor a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion. NTRK gene fusions should be identified by a sufficiently validated test.

March 24, 2021 Off

Bayer’s NTRK fusion-positive tumor drug approved in Japan

By Dino Mustafić

Bayer has announced that the Japanese Ministry of Health, Labor and Welfare (MHLW) has granted marketing authorization for larotrectinib, under the brand name Vitrakvi, for the treatment of Neurotrophic Tyrosine Receptor Kinase (NTRK) fusion-positive advanced or recurrent solid tumors.

December 4, 2019 Off

Bayer tranforming IT function to digitalize

By Dino Mustafić

Bayer said Wednesday it is transforming its IT function to further accelerate the digitalization of the company, by which leading IT providers will take over standardized services, such as the provision of digital workplaces for employees or the global operation of IT infrastructure.

September 16, 2019 Off

Accenture and Bayer streamline drug development processes through Intient clinical platform

By BusinessWire

Accenture (NYSE: ACN) has announced a collaboration with Bayer to implement the Accenture INTIENT Clinical platform to help simplify and speed its drug development processes. The platform, which went live at Bayer earlier this year, brings internal and external clinical data together with Oracle cloud-based technologies into a single data management and warehousing platform, creating actionable insights to accelerate drug development and improve patient outcomes.